Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders

[1]  F. Wong,et al.  Conservative post‐natal management of antenatally diagnosed congenital pulmonary airway malformations , 2018, Journal of paediatrics and child health.

[2]  M. Lucero,et al.  Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series , 2017, The Lancet. Global health.

[3]  M. Lucero,et al.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study , 2017, The Lancet.

[4]  S. Eaton,et al.  Current Management of Congenital Pulmonary Airway Malformations: A “European Pediatric Surgeons' Association” Survey , 2017, European Journal of Pediatric Surgery.

[5]  M. Ashworth,et al.  The natural history of prenatally diagnosed congenital cystic lung lesions: long-term follow-up of 119 cases , 2017, Archives of Disease in Childhood.

[6]  H. Zar,et al.  Respiratory syncytial virus hospitalization and mortality: Systematic review and meta‐analysis , 2016, Pediatric pulmonology.

[7]  M. Maule,et al.  Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study , 2017, The Pediatric infectious disease journal.

[8]  X. Wu,et al.  Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation , 2016, PloS one.

[9]  X. Wu,et al.  Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation , 2016, PloS one.

[10]  L. Bont,et al.  Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries , 2016, Infectious Diseases and Therapy.

[11]  E. Simões,et al.  SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis , 2016, American Journal of Perinatology.

[12]  C. Ambrose,et al.  Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997–2012 , 2016, PloS one.

[13]  Joan L. Robinson,et al.  Author's Response to Letter to the Editor: Re: Robinson JL, Le Saux N. Preventing Hospitalizations for Respiratory Syncytial Virus (RSV) Infection. Canadian Paediatric Society Infectious Diseases and Immunization Committee. Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. , 2016 .

[14]  E. Baraldi,et al.  Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) , 2015, Italian Journal of Pediatrics.

[15]  K. Lanctôt,et al.  Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab , 2015, The Pediatric infectious disease journal.

[16]  Robinson Jl,et al.  Preventing hospitalizations for respiratory syncytial virus infection. , 2015 .

[17]  J. F. Aloy,et al.  Update of recommendations on the use of palivizumab as prophylaxis in RSV infections , 2015 .

[18]  J. F. Aloy.  La Neonatología, primera Área de Capacitación Específica de la Pediatría en España , 2015 .

[19]  J. Figueras Aloy.  [Neonatology, the first specific training area of paediatrics in Spain]. , 2015, Anales de Pediatría.

[20]  Joan L. Robinson,et al.  Preventing hospitalizations for respiratory syncytial virus infection. , 2015, Paediatrics & child health.

[21]  Jin Xu,et al.  Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants , 2014, World Journal of Pediatrics.

[22]  Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection , 2014, Pediatrics.

[23]  Eneida A. Mendonça,et al.  Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection , 2014, Pediatrics.

[24]  M. Gaboli,et al.  Use of palivizumab in infants and young children with severe respiratory disease: A delphi study , 2014, Pediatric pulmonology.

[25]  G. Robbie,et al.  Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. , 2013, Pulmonary pharmacology & therapeutics.

[26]  K. Poehling,et al.  Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of Age , 2013, Pediatrics.

[27]  M. Rojas-Reyes,et al.  Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. , 2013, The Cochrane database of systematic reviews.

[28]  G. Losonsky,et al.  Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children , 2012, Antimicrobial Agents and Chemotherapy.

[29]  E. Simões,et al.  Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Boscoe M. Paes,et al.  Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations , 2011, European Journal of Pediatrics.

[31]  K. Lanctôt,et al.  CARESS: The Canadian Registry of Palivizumab , 2011, The Pediatric infectious disease journal.

[32]  K. Thorburn.  Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection , 2008, Archives of Disease in Childhood.

[33]  Samuel J Daniel,et al.  The upper airway: congenital malformations. , 2006, Paediatric respiratory reviews.

[34]  C. Hartnick,et al.  The potential impact of palivizumab on pediatric airway reconstruction. , 2006, American journal of otolaryngology.

[35]  R. Hirsch,et al.  Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry , 2003, Pediatric pulmonology.

[36]  A. Bush,et al.  Respiratory syncytial virus infections in the pediatric intensive care unit: Clinical characteristics and risk factors for adverse outcomes , 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[37]  E. Eber,et al.  Adult outcome of congenital lower respiratory tract malformations , 2002 .

[38]  B. Mellen,et al.  Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. , 2000, The Journal of pediatrics.

[39]  J. Ludemann,et al.  Complications of Pediatric Laryngotracheal Reconstruction: Prevention Strategies , 1999, The Annals of otology, rhinology, and laryngology.

[40]  E. Wang,et al.  Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. , 1999, The Pediatric infectious disease journal.

[41]  R. Ariagno,et al.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. , 1998, The Pediatric infectious disease journal.